HC Wainwright Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $192.00

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective reduced by HC Wainwright from $198.00 to $192.00 in a report issued on Thursday,Benzinga reports. They currently have a buy rating on the stock.

NBIX has been the topic of a number of other research reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Neurocrine Biosciences in a report on Thursday, January 22nd. UBS Group lowered their price objective on Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Truist Financial reduced their target price on shares of Neurocrine Biosciences from $172.00 to $169.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. TD Cowen lifted their price target on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, December 5th. Finally, Citigroup boosted their price objective on shares of Neurocrine Biosciences from $175.00 to $203.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Sixteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $177.42.

Neurocrine Biosciences Trading Up 0.8%

NASDAQ:NBIX opened at $124.12 on Thursday. The company has a 50-day moving average price of $140.14 and a 200-day moving average price of $140.44. Neurocrine Biosciences has a 12 month low of $84.23 and a 12 month high of $160.18. The stock has a market cap of $12.46 billion, a price-to-earnings ratio of 26.64, a P/E/G ratio of 0.58 and a beta of 0.31.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.36 by ($0.48). Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The company had revenue of $805.50 million for the quarter, compared to analysts’ expectations of $804.21 million. During the same quarter in the prior year, the firm earned $1.69 EPS. Neurocrine Biosciences’s quarterly revenue was up 28.3% compared to the same quarter last year. Equities analysts forecast that Neurocrine Biosciences will post 4.28 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Leslie V. Norwalk sold 1,190 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $155.09, for a total transaction of $184,557.10. Following the sale, the director directly owned 6,239 shares of the company’s stock, valued at $967,606.51. This trade represents a 16.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Darin Lippoldt sold 4,376 shares of Neurocrine Biosciences stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $159.65, for a total value of $698,628.40. Following the completion of the sale, the insider owned 43,405 shares of the company’s stock, valued at $6,929,608.25. The trade was a 9.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 61,966 shares of company stock valued at $8,625,166. 4.80% of the stock is currently owned by company insiders.

Institutional Trading of Neurocrine Biosciences

Institutional investors have recently made changes to their positions in the stock. USA Financial Formulas purchased a new position in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $25,000. Geneos Wealth Management Inc. grew its position in Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares during the period. Golden State Wealth Management LLC raised its stake in Neurocrine Biosciences by 120.5% during the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock valued at $26,000 after buying an additional 100 shares during the last quarter. Eastern Bank bought a new position in shares of Neurocrine Biosciences during the 3rd quarter valued at $27,000. Finally, DJE Kapital AG bought a new position in shares of Neurocrine Biosciences during the 4th quarter valued at $28,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

More Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Multiple analysts reiterated Buy/Outperform ratings and raised some price targets (Citigroup to $204, Bank of America reiterated Buy with a $190 target, Needham nudged to $185), signaling continued confidence in Ingrezza durability and pipeline upside. Analyst moves (Benzinga / TipRanks)
• Positive Sentiment: Q4 revenue grew strongly (~28% YoY to ~$805.5M) and company commentary highlighted Ingrezza sales growth and emerging uptake of pipeline assets — supports longer-term revenue trajectory. Earnings highlights (Yahoo)
• Neutral Sentiment: Deeper analysis pieces discuss growth beyond Ingrezza and portfolio opportunities that could drive medium-term upside but caution that 2026 may be less eventful. Useful for investors assessing longer-horizon thesis. Seeking Alpha: Growth Beyond Ingrezza
• Neutral Sentiment: Full Q4 earnings call transcripts and analyst note compilations are available for investors wanting primary commentary on guidance, expense cadence, and pipeline timelines. Review for detail before trading on headlines. Earnings transcripts & summaries
• Negative Sentiment: EPS missed expectations (Q4 EPS ~$1.88 vs. several consensus figures higher), and management issued cautious 2026 guidance — the combination sparked downside pressure and short-term uncertainty. Zacks: Q4 EPS lag
• Negative Sentiment: Some firms trimmed price targets or downgraded to Market Perform (BMO to $140; RBC and Wells Fargo trimmed targets though keeping Outperform/Overweight designations), reflecting more cautious near-term outlooks. Price target changes (Benzinga)
• Negative Sentiment: Market commentary highlights the stock’s sharp pullback after guidance and the EPS miss — articles explaining recent 8%+ decline underscore the sentiment risk if sales or cost pressures persist. AAII: Why NBIX is down

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.